Blockade of the Serotonin Transporter, but Not Dopamine or Norepinephrine Transporters, Yields Anti-Dyskinetic Effects in L-DOPA Treated Hemiparkinsonian Rats.
Friday, November 7, 2014
Plaza Foyer (Sheraton)
Dopamine replacement therapy with L-DOPA is the standard treatment for Parkinson's Disease; however, it leads to the development of debilitating involuntary movements. This study looked at the possibility of mediating these negative side effects via several transporters in the brain that are responsible for regulating L-DOPA derived dopamine.